GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (NAS:XOMAO.PFD) » Definitions » Debt-to-Equity

XOMAO.PFD (XOMA Royalty) Debt-to-Equity : 1.40 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is XOMA Royalty Debt-to-Equity?

XOMA Royalty's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $10.26 Mil. XOMA Royalty's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $108.68 Mil. XOMA Royalty's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $84.81 Mil. XOMA Royalty's debt to equity for the quarter that ended in Sep. 2024 was 1.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for XOMA Royalty's Debt-to-Equity or its related term are showing as below:

XOMAO.PFD' s Debt-to-Equity Range Over the Past 10 Years
Min: -21.08   Med: 0.25   Max: 19.11
Current: 1.4

During the past 13 years, the highest Debt-to-Equity Ratio of XOMA Royalty was 19.11. The lowest was -21.08. And the median was 0.25.

XOMAO.PFD's Debt-to-Equity is ranked worse than
91.3% of 1023 companies
in the Biotechnology industry
Industry Median: 0.14 vs XOMAO.PFD: 1.40

XOMA Royalty Debt-to-Equity Historical Data

The historical data trend for XOMA Royalty's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Debt-to-Equity Chart

XOMA Royalty Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.25 - - 1.40

XOMA Royalty Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.40 1.47 1.22 1.40

Competitive Comparison of XOMA Royalty's Debt-to-Equity

For the Biotechnology subindustry, XOMA Royalty's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Royalty's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Debt-to-Equity falls into.



XOMA Royalty Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

XOMA Royalty's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

XOMA Royalty's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XOMA Royalty  (NAS:XOMAO.PFD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


XOMA Royalty Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA Royalty Business Description

Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Executives
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Matthew D Perry director, other: See Explanation of Responses ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104